Meritage Portfolio Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Meritage Portfolio Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$15.9M	Sell	20,580 -361	-2%	-$245K	1.05%	12
2025 Q3	$11.8M	Buy	20,941 +9,486	+83%	+$5.36M	0.78%	27
2025 Q2	$6.01M	Buy	+11,455	New	+$6.39M	0.38%	68
2024 Q2	–	Sell	-595	Closed	-$573K	–	346
2024 Q1	$573K	Hold	595	–	–	0.04%	237
2023 Q4	$523K	Hold	595	–	–	0.03%	246
2023 Q3	$490K	Hold	595	–	–	0.04%	240
2023 Q2	$428K	Hold	595	–	–	0.03%	256
2023 Q1	$489K	Hold	595	–	–	0.04%	212
2022 Q4	$429K	Buy	595 +8	+1%	+$5.9K	0.03%	220
2022 Q3	$404K	Buy	+587	New	+$369K	0.03%	225
2022 Q2	–	Sell	-16,733	Closed	-$11.7M	–	339
2022 Q1	$11.7M	Buy	+16,733	New	+$10.6M	0.72%	25
2020 Q3	–	Sell	-10,082	Closed	-$6.29M	–	239
2020 Q2	$6.29M	Buy	+10,082	New	+$5.72M	0.6%	41

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Meritage Portfolio Management's REGN Position: Q4 2025 in Review

Meritage Portfolio Management reduced its Regeneron Pharmaceuticals (REGN) stake by 1.7% in Q4 2025, selling an estimated $245K and leaving 20,580 shares worth $15.9M. The position accounts for 1.05% of the portfolio, ranked #12.

Meritage Portfolio Management first reported a position in REGN in Q2 2020 and has held it in 12 quarters since. 1,385 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

Meritage Portfolio Management held 20,580 shares of Regeneron Pharmaceuticals worth $15.9M as of Q4 2025.
Meritage Portfolio Management sold 361 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $245K.
Regeneron Pharmaceuticals made up 1.05% of Meritage Portfolio Management's portfolio in Q4 2025, its #12 holding.
Meritage Portfolio Management first reported a position in Regeneron Pharmaceuticals in Q2 2020 and has held it in 12 quarters since.
1,385 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on Meritage Portfolio Management's 13F filing for Q4 2025, filed 27 Jan 2026.